Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Moody's Corporation — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Moody's Corporation trades at $463.46 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 6.3× Halozyme Therapeutics Inc. Common Stock's market cap, and Moody's Corporation pays a 0.9% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Moody's Corporation for 132 Days on average.
| HALO | MCO | |
|---|---|---|
Market Cap | $12.58B | $79.44B |
Volume | 2,179,278 | 526,684 |
Sector | Health | Financials |
52-Week High | $115.22 | $539.61 |
52-Week Low | $61.63 | $412.23 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $14.49B | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MCO trades at $460.91, up 2.51% today, with a bearish technical signal but strong fundamentals including a 34.25% net income margin and consistent earnings beats. Revenue grew from $5.5B in 2022 to $7.7B in 2025, with a consensus analyst price target of $536.40. Recent news highlights a Zacks upgrade to Buy and a minority stake acquisition in PhilRatings to expand Asia-Pacific presence.
The outlook is positive given robust profitability and growth, but risks include high valuation multiples and technical weakness. Analysts are predominantly bullish, with 56% Buy ratings, suggesting upside potential if earnings momentum continues, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
